ECSP045156A - Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6 - Google Patents

Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6

Info

Publication number
ECSP045156A
ECSP045156A EC2004005156A ECSP045156A ECSP045156A EC SP045156 A ECSP045156 A EC SP045156A EC 2004005156 A EC2004005156 A EC 2004005156A EC SP045156 A ECSP045156 A EC SP045156A EC SP045156 A ECSP045156 A EC SP045156A
Authority
EC
Ecuador
Prior art keywords
indolilalquilamine
hidroxitriptamina
ligandos
derivatives
receptor
Prior art date
Application number
EC2004005156A
Other languages
English (en)
Inventor
Derek Cecil Cole
Joseph Raymond Stock
William Joseph Lennox
Ping Zhou
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP045156A publication Critical patent/ECSP045156A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) y su uso para el tratamiento terapéutico de desórdenes relacionados o afectados por el receptor 5-HT6.
EC2004005156A 2001-12-20 2004-06-16 Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6 ECSP045156A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34290701P 2001-12-20 2001-12-20

Publications (1)

Publication Number Publication Date
ECSP045156A true ECSP045156A (es) 2004-07-23

Family

ID=23343804

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005156A ECSP045156A (es) 2001-12-20 2004-06-16 Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6

Country Status (29)

Country Link
US (2) US6770642B2 (es)
EP (1) EP1455779B1 (es)
JP (1) JP4335684B2 (es)
KR (1) KR100985140B1 (es)
CN (1) CN1309385C (es)
AR (1) AR037906A1 (es)
AT (1) ATE335477T1 (es)
AU (1) AU2002357270B2 (es)
BR (1) BR0215222A (es)
CA (1) CA2470863C (es)
CO (1) CO5590924A2 (es)
CY (1) CY1105705T1 (es)
DE (1) DE60213856T2 (es)
DK (1) DK1455779T3 (es)
EC (1) ECSP045156A (es)
ES (1) ES2269827T3 (es)
HU (1) HUP0402640A3 (es)
IL (1) IL162243A0 (es)
MX (1) MXPA04005889A (es)
NO (1) NO330338B1 (es)
NZ (1) NZ533666A (es)
PL (1) PL210413B1 (es)
PT (1) PT1455779E (es)
RU (1) RU2309157C2 (es)
SI (1) SI1455779T1 (es)
TW (1) TWI254705B (es)
UA (1) UA78536C2 (es)
WO (1) WO2003053433A1 (es)
ZA (1) ZA200405731B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340743A4 (en) * 2000-11-09 2007-04-25 Mitsui Chemicals Inc OPTICALLY ACTIVE AMINO DERIVATIVE AND METHOD OF SYNTHESIS
TW200301251A (en) * 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
EP1654258A1 (en) * 2003-07-23 2006-05-10 Wyeth Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
WO2005012311A1 (en) * 2003-07-31 2005-02-10 Wyeth N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands
CA2534649A1 (en) * 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
PL1704154T3 (pl) * 2004-01-02 2009-10-30 Suven Life Sciences Ltd Nowe indeno[2,1a]indeny i izoindolo[2,1-a]indole
PE20060303A1 (es) * 2004-06-23 2006-05-19 Wyeth Corp Metabolitos de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
AU2005316675A1 (en) * 2004-12-14 2006-06-22 Wyeth Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders
US20060211698A1 (en) * 2005-01-14 2006-09-21 Genelabs, Inc. Bicyclic heteroaryl derivatives for treating viruses
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
BRPI0811225A2 (pt) * 2007-05-24 2014-10-29 Memory Pharm Corp Composto 4'-substituídos tendo afinidade pelo receptor 5-ht6.
EP2016943B1 (en) * 2007-07-19 2011-02-23 Laboratorios del Dr. Esteve S.A. Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
EP2231160B1 (en) * 2007-12-04 2013-08-14 Merck Sharp & Dohme Corp. Tryptamine sulfonamides as 5-ht6 antagonists
JP2011507835A (ja) 2007-12-21 2011-03-10 アンドレイ・アレクサンドロビッチ・イワシェンコ α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
CA2959505A1 (en) * 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
KR102586736B1 (ko) 2014-08-29 2023-10-11 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴을 단백질 영상화하기 위한 프로브
IL311211B1 (en) 2021-09-03 2026-02-01 Alexander Shulgin Res Institute Inc Asymmetric allyl tryptamines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
PL172405B1 (en) * 1992-04-07 1997-09-30 Pfizer Derivatives of indole
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6133287A (en) * 1998-03-24 2000-10-17 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-HT6 affinity
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
EP1204662B1 (en) * 1999-08-12 2004-06-02 NPS Allelix Corp. Azaindoles having serotonin receptor affinity
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
WO2001034146A1 (en) * 1999-11-08 2001-05-17 Smithkline Beecham Corporation Novel anti-infectives

Also Published As

Publication number Publication date
JP4335684B2 (ja) 2009-09-30
WO2003053433A1 (en) 2003-07-03
NO20043100L (no) 2004-08-26
CN1620290A (zh) 2005-05-25
BR0215222A (pt) 2005-05-24
HUP0402640A2 (hu) 2005-04-28
UA78536C2 (en) 2007-04-10
ES2269827T3 (es) 2007-04-01
HK1065949A1 (en) 2005-03-11
CY1105705T1 (el) 2010-12-22
US6770642B2 (en) 2004-08-03
US20040209867A1 (en) 2004-10-21
RU2309157C2 (ru) 2007-10-27
JP2005517661A (ja) 2005-06-16
RU2004122129A (ru) 2005-05-10
CA2470863A1 (en) 2003-07-03
HUP0402640A3 (en) 2012-09-28
AU2002357270A1 (en) 2003-07-09
EP1455779B1 (en) 2006-08-09
CA2470863C (en) 2012-05-15
PL370711A1 (en) 2005-05-30
PT1455779E (pt) 2006-11-30
DE60213856D1 (de) 2006-09-21
AR037906A1 (es) 2004-12-22
ZA200405731B (en) 2007-02-28
CN1309385C (zh) 2007-04-11
AU2002357270B2 (en) 2007-06-14
TW200301252A (en) 2003-07-01
ATE335477T1 (de) 2006-09-15
TWI254705B (en) 2006-05-11
US7022701B2 (en) 2006-04-04
KR20040075892A (ko) 2004-08-30
DK1455779T3 (da) 2006-10-30
EP1455779A1 (en) 2004-09-15
US20030171353A1 (en) 2003-09-11
DE60213856T2 (de) 2007-09-13
CO5590924A2 (es) 2005-12-30
KR100985140B1 (ko) 2010-10-05
NZ533666A (en) 2006-03-31
IL162243A0 (en) 2005-11-20
NO330338B1 (no) 2011-03-28
PL210413B1 (pl) 2012-01-31
SI1455779T1 (sl) 2006-12-31
MXPA04005889A (es) 2004-11-01

Similar Documents

Publication Publication Date Title
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
BR0311591A (pt) 1-(aminoalquil)-2-sulfonilazindóis como ligandos de 5-hidroxitriptamina-6
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
ECSP055851A (es) Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
UY28144A1 (es) Agentes terapéuticos
UY27892A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos.
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
UY28314A1 (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
UY28150A1 (es) Agentes terapeuticos
ECSP055899A (es) Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
BR0213094A (pt) Derivados de cromano como ligandos de 5-hidroxi-triptamina-6
BRPI0418181A (pt) emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
UY29633A1 (es) Derivados de oxindol
UY28377A1 (es) Agentes terapeuticos
BR0209047A (pt) Derivados de heterociclilalcóxi-, -alquiltio- e -alquilaminobenzazol como ligantes de 5-hidroxitriptamina-6